These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 7511798)

  • 1. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth.
    Fotsis T; Zhang Y; Pepper MS; Adlercreutz H; Montesano R; Nawroth PP; Schweigerer L
    Nature; 1994 Mar; 368(6468):237-9. PubMed ID: 7511798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of cytogenin, a novel microbial product, on embryonic and tumor cell-induced angiogenic responses in vivo.
    Oikawa T; Sasaki M; Inose M; Shimamura M; Kuboki H; Hirano S; Kumagai H; Ishizuka M; Takeuchi T
    Anticancer Res; 1997; 17(3C):1881-6. PubMed ID: 9216639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo.
    Vandercappellen J; Liekens S; Bronckaers A; Noppen S; Ronsse I; Dillen C; Belleri M; Mitola S; Proost P; Presta M; Struyf S; Van Damme J
    Mol Cancer Res; 2010 Mar; 8(3):322-34. PubMed ID: 20215425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelial cell growth: biology and pharmacology in relation to angiogenesis.
    Tobelem G
    Blood Coagul Fibrinolysis; 1990 Dec; 1(6):703-5. PubMed ID: 1723309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo.
    Ramakrishnan S; Olson TA; Bautch VL; Mohanraj D
    Cancer Res; 1996 Mar; 56(6):1324-30. PubMed ID: 8640821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin-steroid conjugates: new angiogenesis inhibitors with antitumor activity in mice.
    Thorpe PE; Derbyshire EJ; Andrade SP; Press N; Knowles PP; King S; Watson GJ; Yang YC; Rao-Betté M
    Cancer Res; 1993 Jul; 53(13):3000-7. PubMed ID: 7686447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.
    Ueda Y; Yamagishi T; Ikeya H; Hirayama N; Itokawa T; Aozuka Y; Samata K; Nakaike S; Tanaka M; Ono M; Saiki I
    Anticancer Res; 2004; 24(5A):3009-17. PubMed ID: 15517909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities.
    Sheu JR; Fu CC; Tsai ML; Chung WJ
    Anticancer Res; 1998; 18(6A):4435-41. PubMed ID: 9891506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cimetidine inhibits angiogenesis and suppresses tumor growth.
    Natori T; Sata M; Nagai R; Makuuchi M
    Biomed Pharmacother; 2005; 59(1-2):56-60. PubMed ID: 15740937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel function of ascorbic acid as an angiostatic factor.
    Ashino H; Shimamura M; Nakajima H; Dombou M; Kawanaka S; Oikawa T; Iwaguchi T; Kawashima S
    Angiogenesis; 2003; 6(4):259-69. PubMed ID: 15166494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A diaminoantraquinone inhibitor of angiogenesis.
    Takano S; Gately S; Jiang JB; Brem S
    J Pharmacol Exp Ther; 1994 Nov; 271(2):1027-33. PubMed ID: 7525934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tetraarsenic oxide, a novel orally administrable angiogenesis inhibitor.
    Park MJ; Park IC; Bae IJ; Seo KM; Lee SH; Hong SI; Eun CK; Zhang W; Rhee CH
    Int J Oncol; 2003 Jun; 22(6):1271-6. PubMed ID: 12738993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
    Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington
    Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
    Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
    Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.